AVEO's Cancer Drug Hits Key Milestone in Head & Neck Cancer Trial

BOSTON, MA – February 18, 2026 – AVEO Oncology, an LG Chem company, has reached a significant milestone in its pivotal Phase 3 clinical trial for ficlatuzumab, a promising new drug for a notoriously difficult-to-treat form of head and neck cancer. The company announced today that following a planned interim analysis, a specific dose has been selected to move forward, advancing the global study and offering a renewed sense of hope for a patient population with critically limited options.

The decision clears a crucial hurdle in the FIERCE-HN study, a large-scale registrational trial evaluating ficlatuzumab in patients with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) that is not caused by the human papillomavirus (HPV). This progress is a key step in what could become a new therapeutic standard for a disease with a grim prognosis.

A Critical Step in a High-Stakes Trial

The FIERCE-HN trial is a global, randomized, double-blind study designed to rigorously test the efficacy and safety of ficlatuzumab. The announcement confirmed that the study's first planned interim analysis has been completed, leading to the selection of a 20mg/kg dose of ficlatuzumab. This dose will be administered in combination with ERBITUX® (cetuximab), a widely used cancer therapy, and compared against a group receiving a placebo plus cetuximab.

This milestone is far more than a routine update. In late-stage drug development, interim analyses are critical checkpoints reviewed by an Independent Data Monitoring Committee (IDMC), a panel of outside experts. The IDMC's recommendation to proceed with the 20mg/kg dose, a decision aligned with the U.S. Food & Drug Administration (FDA), signifies that the trial has passed an early test for futility and has identified an optimal dose to carry forward. This de-risks the program to a degree and allows AVEO to focus its resources on the most promising path toward potential approval.

"This is a significant milestone for AVEO, as we are dedicated to improving patient outcomes through novel clinical research," said Michael P. Bailey, President and CEO of AVEO, in a statement. "The selection of the ficlatuzumab dose in combination with cetuximab advances us towards understanding the potential clinical value of this combination in a patient population that has limited effective treatment options available to them today."

With this decision made, global enrollment for the trial, which aims to include 410 to 500 patients, will continue with renewed focus.

Targeting a Formidable Foe

Head and neck squamous cell carcinoma is the sixth most common cancer worldwide. While some cases are linked to HPV and have a relatively better prognosis, HPV-negative HNSCC—often tied to long-term tobacco and alcohol use—presents a much graver challenge. For patients whose cancer has returned or spread, the median overall survival is often just over a year, even with the best available treatments.

The FIERCE-HN trial is specifically enrolling patients who have already exhausted standard therapies, including platinum-based chemotherapy and powerful immune checkpoint inhibitors like Keytruda® or Opdivo®. For this "pan-refractory" group, the therapeutic arsenal is nearly empty, making the search for new options a matter of extreme urgency.

Dr. Julie E. Bauman, the principal investigator for the trial and Director of the George Washington Cancer Center, highlighted the importance of this progress. "Today's announcement is a defining moment and one that brings us one step closer to determining the potential clinical benefit of the combination of ficlatuzumab and cetuximab in this underserved population," she commented. "While I remain a blinded investigator, identifying the optimal dose is a significant inflection point for the clinical trial. We are keen on completing enrollment and continuing to advance the FIERCE-HN study."

Further details on the trial's design will be shared at the upcoming Multidisciplinary Head and Neck Cancers Symposium in Palm Desert, California, where Dr. Bauman is scheduled to present a "Trials in Progress" poster.

The Science of a Dual-Pronged Attack

The scientific rationale behind the FIERCE-HN trial is rooted in overcoming a common mechanism of cancer drug resistance. The trial combines ficlatuzumab with cetuximab, an antibody that works by blocking the epidermal growth factor receptor (EGFR), a protein that fuels tumor growth in about 90% of HNSCC cases. However, tumors are notoriously clever and often develop "escape routes" to bypass such blockades.

One of the primary escape routes involves a different signaling pathway known as HGF/c-Met. Research has shown that when the EGFR pathway is blocked by drugs like cetuximab, cancer cells can ramp up signaling through the HGF/c-Met pathway to continue their growth and spread. Ficlatuzumab is an investigational antibody specifically designed to inhibit this escape route by targeting and neutralizing hepatocyte growth factor (HGF), the ligand that activates the c-Met receptor.

By combining ficlatuzumab and cetuximab, AVEO is testing a dual-pronged strategy: simultaneously blocking the primary growth pathway (EGFR) and the key escape pathway (HGF/c-Met). The hypothesis is that this one-two punch could be more effective than either approach alone, potentially re-sensitizing tumors to treatment and improving patient outcomes. This innovative approach was compelling enough for the FDA to grant the combination Fast Track designation back in September 2021, a status designed to expedite the development of drugs addressing serious unmet needs.

This strategy is not just theoretical. It is supported by data from a prior Phase 2 study, which showed a statistically significant benefit in progression-free survival for patients receiving the combination therapy. Notably, the benefit was most pronounced in the HPV-negative patient subgroup, providing the strong scientific foundation for the current, larger Phase 3 trial.

A Key Asset in LG Chem's Global Ambition

This clinical milestone is also a significant development for AVEO's parent company, the South Korean conglomerate LG Chem. In a landmark deal that closed in early 2023, LG Chem acquired AVEO for approximately $571 million, a move explicitly designed to establish a commercial oncology footprint in the lucrative U.S. market and bolster its life sciences division.

The acquisition brought AVEO's already-marketed kidney cancer drug, FOTIVDA®, into LG Chem's portfolio, providing an immediate revenue stream. However, the long-term value of the deal was also heavily dependent on the success of AVEO's pipeline, with ficlatuzumab being a central asset. LG Chem has publicly stated its ambition to become a top-tier global biopharmaceutical company, earmarking over $1.5 billion for investment in its life sciences business through 2027.

The steady progress of the FIERCE-HN trial serves as an early validation of that high-stakes investment. It demonstrates that the pipeline LG Chem acquired is advancing as planned and holds the potential to deliver a high-value asset in a major oncology market. A successful outcome for ficlatuzumab would not only provide a much-needed treatment for patients but also solidify LG Chem's strategy and position its life sciences division as a serious contender on the global stage. As the FIERCE-HN trial continues to enroll patients worldwide, it will be watched closely by clinicians, patients, and investors alike.